{"id":"W4206922330","doi":"10.1200/jco.2022.40.36_suppl.359881","title":"INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deciphera Pharmaceuticals","keywords":"Medicine; Sunitinib; GiST; Imatinib; Internal medicine; Clinical endpoint; Population; Imatinib mesylate; Interim analysis; Oncology; Randomization; Tyrosine-kinase inhibitor; Gastroenterology; Surgery; Randomized controlled trial; Cancer; Stromal cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008828972,0.0002850324,0.002753238,0.0002204798,0.0001422691,0.0000228276,0.0004375875,0.00002176027,0.0001533765],"category_scores_gemma":[0.009734856,0.00014518,0.000131621,0.000469768,0.0004792605,0.0001135682,0.0003808909,0.001361818,0.000001483183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000268311,"about_ca_system_score_gemma":0.001712541,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001231201,"about_ca_topic_score_gemma":0.0001020516,"domain_scores_codex":[0.9923198,0.003090043,0.0026896,0.0003695267,0.001056238,0.0004748387],"domain_scores_gemma":[0.988378,0.007924337,0.001781531,0.0003444732,0.0009531571,0.0006185063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7966692,0.03627947,0.1512644,0.00001513539,0.0005007593,0.002087057,0.0002662764,0.00009336846,0.00001168159,0.0000113506,0.00004200137,0.01275931],"study_design_scores_gemma":[0.5612568,0.3149568,0.1209389,0.0002753245,0.0006238486,0.0007947733,0.0009308035,0.0001045828,0.000004425609,0.000005337653,0.00003640058,0.00007202295],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920725,0.00004258678,0.00004787677,0.001029797,0.00006518218,0.006382001,0.00002372441,0.000007239501,0.0003291132],"genre_scores_gemma":[0.9911481,0.000009122882,0.008394663,0.0001510515,0.00005624102,0.0001700533,0.00001396,0.00002756865,0.00002930663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2786773,"threshold_uncertainty_score":0.9986066,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09788494523111237,"score_gpt":0.4694314721276791,"score_spread":0.3715465268965667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}